

Protocol Summary for Out-of-Province Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors

Protocol Code

GINPRRT

Tumour Group

Gastrointestinal

Contact Physician

Dr. Sharlene Gill

ELIGIBILITY:

- Well to moderately differentiated advanced neuroendocrine tumors with progressive and or symptomatic carcinoid syndrome despite [octreotide long acting](#) therapy and/or radiographic progressive disease
- Confirmed octreotide-avid disease by octreoscan (for treatment with Lutetium ¹⁷⁷-octreotate) and/or mIBG-avid disease by mIBG scan (for treatment with ¹³¹I-mIBG)
- Not a candidate for curative-intent surgical options
- Ki67 less than or equal to 20% and mitotic count <20/HPF
- Documented approval at [BC Cancer](#) provincial or regional GI conference
- Patient willing to travel to Edmonton for therapy
- Requires out-of-province funding approval (not a [BC Cancer](#) Benefit List drug)

EXCLUSIONS:

- Platelets less than 100
- Hemoglobin less than 90
- ECOG PS greater than 1
- Creatinine clearance or glomerular filtrate rate (GFR) less than 50 mL/min

TESTS:

- CBC and diff, platelets, electrolytes, creatinine, BUN, bilirubin, AST, LDH, alkaline phosphatase, INR, albumin
- Serum chromogranin A
- 24 urine 5HIAA
- Octreotide and mIBG scan within the past 6 months
- CT/MRI within the past 6 months

TREATMENT:

Up to 4 cycles of therapy are given at minimum intervals of 4 to 6 weeks. Further therapy is subject to re-approval for out-of-province funding.

Patients are referred to the Cross Cancer Institute in Edmonton, AB for consideration of radioisotope therapy. For referral, please forward the following:

- Pathology report(s)
- Operative report(s)
- Consultation note documenting history, comorbidities, medications and ECOG
- Results of recent laboratory and urine tests as listed above
- Octreotide and mIBG scan – images and report (on CD)
- CT/MRI – images and report (on CD)
- Demographics and contact information for the patient

Send by courier to:

Nuclear Medicine Therapy Coordinator
Neuroendocrine Tumor Clinic Coordinator
Cross Cancer Institute
11560 University Avenue
Edmonton, AB T6G 1Z2

Call GI tumour group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS consensus guidelines for the standard of care in neuroendocrine tumours: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. *Neuroendocrinology* 2009;90:220-6.